Transformation of medical education and training of highly qualified personnel discussed at the Uzbek-Russian Medical Forum
A breakout session on transformation of medical education, and training of highly qualified medical personnel, held on June 3 in Samarkand, was attended by Vladislav Shestakov, Director of the FSI “State Institute of Drugs and Good Practices” of the Ministry of Industry and Trade of Russia.
Since 2015, the FSI “SID & GP” has been an authorized institution for conducting pharmaceutical inspections of manufacturers of human medicines located outside the Russian Federation for compliance with the requirements of the Good Manufacturing Practice rules. This year the institution is celebrating its 50th anniversary, and its history emphasizes the importance of high-quality medical and pharmaceutical education.
Nowadays, there is a Russian pharmaceutical inspectorate of 60 employees formed at the premises of the Institute, who have already conducted about 3,200 inspections of production sites in 73 countries around the world.
Vladislav Shestakov noted that there was a shortage of highly qualified personnel, both while the inspectorate was being formed and during its operation. “A modern pharmaceutical site is a high-tech manufacturing, where the knowledge of employees becomes outdated in 3 years on average. Therefore, inspectors need to improve their qualification with even a higher frequency, and this is a separate programme of continuing education,” he said.
To address this issue, the Eurasian Academy of Good Practices was established in 2021, with the support of the FSI “SID & GP”. The Academy annually implements more than 40 professional development programmes with a practice-oriented approach. In 2022, the certificates were received by over 430 people, of which 15% were international students.
“I would like to emphasize that the Academy, with the assistance from the SID & GP inspectors, implemented a 175-hour training programme on the requirements of Good Manufacturing Practices regulations for pharmaceutical inspectors in the Republic of Uzbekistan in 2021-2022,” the speaker informed. The practical part has been carried out at pharmaceutical sites in the Republic of Uzbekistan. Training on “Pharmacovigilance in pharmaceutical manufacturing” was also conducted.
One of the high-tech educational innovations used by the Academy in the educational process is the VR facility, which, with the help of augmented virtual reality, allows you to sharpen the necessary skills. The complex shows all the manufacturing stages of solid dosage forms. “And now an innovative simulation complex “Virtual Facility 2.0. Biotechnology Manufacturing” is being finalised,” Vladislav Shestakov marked.
The speaker noted that while having a high level of academic training, today’s students are sorely lacking practice. A large number of restricted access internal procedures at sites makes it impossible to train relevant students in a real manufacturing activities. Realizing this, the Eurasian Academy of Good Practices, together with the FSI “SID & GP”, has developed a unique simulation complex “Virtual Pharmaceutical Facility for Universities”. In a virtual environment, students have a unique opportunity to visit restricted access production sites where interns and trainees are not usually allowed.
“We are ready for further fruitful cooperation with colleagues from the Republic of Uzbekistan, for joint inspections and workshops. And, of course, we invite you to study at the Eurasian Academy of Good Practices,” Vladislav Shestakov said in conclusion.
Other materials
- International Forum of Pharmaceutical Inspectorates: A Step Towards Global Harmonization of Standards
- FSI “SID & GP” and CDSCO, India signed a cooperation agreement.
- The importance of reference samples in the development of pharmaceutical industry was discussed during the meeting of the Healthcare Commission of the General Council of the UNITED RUSSIA Party
- The program of the IX All-Russian GMP Conference with international participation has been published
- Attendees of the ‘Ensuring Drug Security’ Forum discussed issues of public trust in the Russian pharmaceutical products